SLC5A2 and hydrops fetalis: SGLT2 inhibitors target cardiometabolic conditions through a variety of mechanisms, and have been shown to reduce the risk of cardiovascular (CV) death or worsening HF, and to improve health status in patients with HF with reduced ejection fraction (HFrEF), regardless of diabetes status10–13.